In brief
Researchers at the Garvan Institute examined over 400 estrogen‑receptor positive breast cancer biopsies and found that increased activity of the cell‑division protein CDK1 correlated with more aggressive disease and worse survival. The findings suggest that CDK1 could serve as a biomarker for predicting which patients will not benefit from the commonly used CDK4/6 inhibitor class, offering a path toward more personalized therapy. Larger trials are needed to confirm the predictive value and explore CDK1‑targeted treatments.
A study released by the Garvan Institute of Medical Research in Sydney has identified the activity of the protein CDK1 as a potential marker for determining how estrogen‑receptor positive (ER+) breast cancers respond to CDK4/6 inhibitors, a common class of targeted chemotherapy drugs. The researchers analyzed more than 400 biopsy samples and found that higher levels of CDK1 activity were associated with more aggressive tumors and poorer patient outcomes.
In breast cancer, estrogen hormones stimulate tumor growth in the majority of ER+ cases, making hormone therapy a standard component of treatment. To slow cell proliferation further, many patients receive CDK4/6 inhibitors, drugs that block specific cell cycle proteins and have improved survival rates. However, not every patient benefits, and resistance typically develops over time.
The Garvan study focused on the biology of CDK1, an enzyme that controls a key checkpoint in the cell division cycle. Unlike CDK4 and CDK6, whose activity is directly targeted by the approved drugs, CDK1 has not been considered a therapeutic target for breast cancer. By measuring the levels of CDK1 activity in tumor tissues, the research team observed a clear trend: as tumors became more aggressive, CDK1 activity rose, and patients whose tumors displayed the highest activity ultimately faced worse prognoses.
Because CDK1 functions distinctly from CDK4/6, its elevated activity may indicate that downstream pathways have adapted to bypass CDK4/6 inhibition, effectively rendering the therapy ineffective. The study proposes that measuring CDK1 could identify patients unlikely to benefit from CDK4/6 inhibitors before treatment initiation, allowing clinicians to tailor more effective regimens.
While the findings were presented in the peer‑reviewed journal Advanced Science, the researchers caution that the results stem from an observational analysis of tumor samples and that prospective, larger‑scale clinical trials are essential to validate CDK1 as a predictive biomarker. The next logical step would involve enrolling patients in a study where CDK1 activity is assessed prior to therapy, followed by monitoring treatment response and survival outcomes.
If subsequent trials confirm the predictive value of CDK1, the scientific community may explore dual therapy strategies that simultaneously inhibit both CDK4/6 and CDK1, potentially preventing the development of drug resistance. In the meantime, the study provides a promising avenue for more precise stratification of ER+ breast cancer patients, improving the likelihood that each individual receives the most effective treatment plan.
